DEFINIUM THERAPEUTICS INC (DFTX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for DFTX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| DFTX | Board Chair; Chair of the Board | 69 | ["Chair of the board of trustees of McLean Hospital (affiliate of Harvard Medical School)","Member of the board of trustees of Mass General Brigham","Chair of the board of directors of RiaHealth and CrowdComfort","Board member of Bain Capital double impact portfolio company, Arosa; and Hightop Health","Former board member of Cresco Labs, Inc.","Industry Advisor for Berkshire Partners","Advisory Board member for Longitude Capital","Chair of the Board of the Company","Industry advisor for Berkshire Partners","advisory board member for Longitude Capital"] | ["Compensation Committee","Audit Committee","board of trustees of McLean Hospital","finance committee for Mass General Brigham","compensation committee of Cresco Labs, Inc.","executive committee of Cresco Labs, Inc.","board of Bain Capital Double Impact portfolio company, Arosa","board of HighTop Health","board of SV Health Investors’ portfolio company, Ria Health","board of CrowdComfort"] | 2026 |
Biography sourced from the proxy statement filing.
Carol A. Vallone has served as a director of the Company since September 2021 and Chair of the Board since December 2021. Ms. Vallone has served as a Trustee at McLean Hospital, the US News & World Report #1 psychiatric hospital in the nation, and the largest psychiatric affiliate of Harvard Medical School, since June 2007 and has served as Chair of the Board of Trustees at McLean Hospital since March 2018. She also serves on the board of trustees of Mass General Brigham, an integrated healthcare system, since July 2022 and currently serves on the Strategic Capital Management Committee and the Development Committee. Additionally, Ms. Vallone has served as a board member for a Bain Capital Double Impact portfolio company, Arosa, since June 2019, and as a board member for HighTop Health since September 2023. She has been Chair of the Board of Ria Health, a SV Health Investors portfolio company since June 2022, and Chair of the Board of CrowdComfort since September 2023. In addition, Ms. Vallone served as a board member for the publicly traded medical marijuana company Cresco Labs (CSE: CL) from July 2020 until July 2024. She is an Industry Advisor for the investment firm, Berkshire Partners, an Advisory Board Member of the healthcare-focused venture growth firm, Longitude Capital, and a Senior Advisor to Oxford Medical Simulation. Ms. Vallone has served as founder and Chief Executive Officer of higher education e-learning companies that she successfully launched, scaled globally and sold; held management positions in leading enterprise technology companies; and served on the boards of a public bank and a private-equity backed e-commerce company that went public. Ms. Vallone earned her Bachelor of Science in Business Administration from the University of Delaware. We believe that Ms. Vallone s strategic, financial, executive and governance experience received from her service on the boards of trustees for nationally ranked psychiatric and medical hospitals; extensive experience building and selling global companies; and experience as a director and advisor to several public and private healthcare services companies make her qualified to serve on our Board.